ValuEngine upgraded shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a hold rating to a buy rating in a report released on Friday.

Several other research analysts also recently commented on AMPH. Zacks Investment Research downgraded Amphastar Pharmaceuticals from a hold rating to a strong sell rating in a research note on Tuesday, May 15th. BidaskClub raised Amphastar Pharmaceuticals from a hold rating to a buy rating in a research note on Saturday, May 19th. Finally, Needham & Company LLC cut their target price on Amphastar Pharmaceuticals from $24.00 to $22.00 and set a buy rating for the company in a research note on Friday, August 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $21.00.

NASDAQ AMPH traded down $0.22 during mid-day trading on Friday, hitting $17.82. The stock had a trading volume of 116,001 shares, compared to its average volume of 200,452. Amphastar Pharmaceuticals has a twelve month low of $14.40 and a twelve month high of $20.45. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.24 and a current ratio of 1.94. The company has a market cap of $801.16 million, a P/E ratio of 46.89, a P/E/G ratio of 3.24 and a beta of 1.40.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Wednesday, August 8th. The company reported $0.03 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.08 by ($0.05). Amphastar Pharmaceuticals had a negative net margin of 3.39% and a positive return on equity of 2.15%. The firm had revenue of $71.00 million during the quarter, compared to analyst estimates of $64.22 million. During the same period in the prior year, the company posted $0.11 earnings per share. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year. sell-side analysts predict that Amphastar Pharmaceuticals will post 0.24 EPS for the current fiscal year.

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 3,250 shares of the firm’s stock in a transaction on Monday, July 9th. The stock was sold at an average price of $16.46, for a total value of $53,495.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael A. Zasloff sold 15,000 shares of the firm’s stock in a transaction on Tuesday, June 12th. The stock was sold at an average price of $16.52, for a total value of $247,800.00. Following the completion of the sale, the director now directly owns 29,845 shares of the company’s stock, valued at $493,039.40. The disclosure for this sale can be found here. Insiders sold a total of 45,056 shares of company stock valued at $763,305 over the last ninety days. Corporate insiders own 31.50% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of AMPH. Sei Investments Co. grew its holdings in shares of Amphastar Pharmaceuticals by 4.9% during the 2nd quarter. Sei Investments Co. now owns 67,934 shares of the company’s stock worth $1,037,000 after purchasing an additional 3,193 shares during the period. Prudential Financial Inc. grew its holdings in shares of Amphastar Pharmaceuticals by 8.4% during the 1st quarter. Prudential Financial Inc. now owns 62,380 shares of the company’s stock worth $1,170,000 after purchasing an additional 4,850 shares during the period. Argent Capital Management LLC grew its holdings in shares of Amphastar Pharmaceuticals by 2.2% during the 2nd quarter. Argent Capital Management LLC now owns 235,775 shares of the company’s stock worth $3,598,000 after purchasing an additional 5,000 shares during the period. Mackay Shields LLC grew its holdings in shares of Amphastar Pharmaceuticals by 2.4% during the 2nd quarter. Mackay Shields LLC now owns 234,500 shares of the company’s stock worth $3,578,000 after purchasing an additional 5,500 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in shares of Amphastar Pharmaceuticals by 2.2% during the 1st quarter. Principal Financial Group Inc. now owns 273,428 shares of the company’s stock worth $5,127,000 after purchasing an additional 5,789 shares during the period. 43.66% of the stock is owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Featured Story: How do investors use RSI to grade stocks?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.